QualityStocksNewsBreaks – Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) Closes $8.0 Million Registered Direct Offering
Estrella Immunopharma (NASDAQ: ESLA, ESLAW) announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor, generating aggregate gross proceeds of approximately $8.0 million. The offering included the issuance of 4,063,290 shares of common stock and 1,000,000 pre-funded warrants, together with a concurrent private placement of common warrants to purchase up to 7,594,935 additional shares, with net proceeds expected to be used for general corporate purposes and working capital as the company advances its CD19 and CD22-targeted ARTEMIS T-cell therapy programs, including lead candidate EB103. Aegis Capital Corp. acted as exclusive placement agent for the…